Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Leukemia 53 Lymphoma 51 Melanoma 44 Breast Neoplasms 37 Lymphoma, Follicular 36 Leukemia, Myeloid, Acute 33 Leukemia, Lymphocytic, Chronic, B-Cell 30 Precursor Cell Lymphoblastic Leukemia-Lymphoma 29 Lymphoma, Non-Hodgkin 29 Neuroblastoma 28 Multiple Myeloma 28 Lymphoma, Large B-Cell, Diffuse 25 Prostatic Neoplasms 23 Lymphoma, Mantle-Cell 23 Myelodysplastic Syndromes 22 Lymphoma, Large-Cell, Immunoblastic 20 Neoplasms, Plasma Cell 19 Leukemia, Myeloid, Chronic-Phase 19 Hodgkin Disease 18 Carcinoma, Non-Small-Cell Lung 18 Burkitt Lymphoma 18 Ovarian Neoplasms 17 Lymphoma, B-Cell, Marginal Zone 17 Lung Neoplasms 17 Neoplasm Metastasis 16 Glioblastoma 16 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 15 Congenital Abnormalities 15 Leukemia, Myeloid, Accelerated Phase 14 Gliosarcoma 12

Interventions

pembrolizumab 14 Injections 13 Paclitaxel 10 Nivolumab 10 Docetaxel 9 Cisplatin 9 Capecitabine 8 Bevacizumab 8 toripalimab 7 senaparib 7 Cyclophosphamide 7 tislelizumab 6 atezolizumab 6 Irinotecan 6 Gemcitabine 5 Fluorouracil 5 fludarabine 4 apatinib 4 Oxaliplatin 4 Leucovorin 4 Ipilimumab 4 Fluorodeoxyglucose F18 4 Carboplatin 4 spartalizumab 3 sintilimab 3 pertuzumab 3 olaparib 3 camrelizumab 3 Rifampin 3 Radiosurgery 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Solid Tumor × sargramostim × Clear all

NCT05284214 2023-09-15

SALIENT

Partner Therapeutics, Inc.

Phase 2 Withdrawn

Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡